A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease

12Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Characterization of patient factors associated with istradefylline efficacy may facilitate personally optimized treatment. Objectives: We aimed to examine which patient factors are associated with favorable istradefylline treatment outcomes in PD patients with motor complications. Methods: We performed a pooled analysis of data from two identical phase 2b and 3 Japanese studies of istradefylline. Logistic regression models were used to assess the association of 12 patient characteristics with favorable outcomes. Results: Off time reduction and increased good on time with istradefylline provided a significantly favorable response in patients aged ≥65 years. Off time reduction was more favorable in patients with ≥8-hour daily off time at baseline. Improvement in UPDRS Part III was favorable in patients with UPDRS Part III baseline score ≥ 20. Conclusions: Several patient factors influenced the effect of istradefylline on motor fluctuations, motor function, activities of daily living, and clinical impression. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Cite

CITATION STYLE

APA

Hattori, N., Kitabayashi, H., Kanda, T., Nomura, T., Toyama, K., & Mori, A. (2020). A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson’s Disease. Movement Disorders, 35(8), 1481–1487. https://doi.org/10.1002/mds.28095

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free